IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by LPL Financial LLC

LPL Financial LLC reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 22.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,537 shares of the company's stock after selling 9,600 shares during the quarter. LPL Financial LLC's holdings in IDEXX Laboratories were worth $13,865,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Rialto Wealth Management LLC purchased a new stake in IDEXX Laboratories during the fourth quarter worth approximately $30,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth about $31,000. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth $38,000. Crews Bank & Trust purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at $41,000. Finally, BankPlus Trust Department acquired a new stake in IDEXX Laboratories during the 4th quarter valued at $60,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on IDXX shares. Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Barclays upped their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Finally, Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Stock Performance

IDXX traded down $14.74 during trading on Monday, reaching $378.99. 1,818,009 shares of the company were exchanged, compared to its average volume of 597,812. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock has a market cap of $30.71 billion, a P/E ratio of 35.52, a PEG ratio of 3.41 and a beta of 1.50. IDEXX Laboratories, Inc. has a 52 week low of $365.93 and a 52 week high of $548.88. The firm has a 50 day moving average of $434.58 and a 200 day moving average of $438.33.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.